Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Thromboprophylaxis after Hospitalization for Medical Illness.

Spyropoulos AC, Barnathan ES, Raskob GE; MARINER Investigators.

N Engl J Med. 2018 Dec 6;379(23):2280. doi: 10.1056/NEJMc1813803. No abstract available.

PMID:
30575454
2.

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.

Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators.

N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26.

3.

A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma.

Kollmeier AP, Barnathan ES, O'Brien C, Chen B, Xia YK, Zhou B, Loza MJ, Silkoff PE, Ge M, Thurmond RL.

Ann Allergy Asthma Immunol. 2018 Nov;121(5):568-574. doi: 10.1016/j.anai.2018.08.001. Epub 2018 Aug 11.

PMID:
30102965
4.

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

Zhu J, Message SD, Mallia P, Kebadze T, Contoli M, Ward CK, Barnathan ES, Mascelli MA, Kon OM, Papi A, Stanciu LA, Edwards MR, Jeffery PK, Johnston SL.

J Allergy Clin Immunol. 2019 Jan;143(1):114-125.e4. doi: 10.1016/j.jaci.2018.04.003. Epub 2018 Apr 24.

5.

Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H4 R-antagonist (JNJ-39758979) in adults with uncontrolled asthma.

Kollmeier AP, Greenspan A, Xu XL, Silkoff PE, Barnathan ES, Loza MJ, Jiang J, Zhou B, Chen B, Thurmond RL.

Clin Exp Allergy. 2018 Aug;48(8):957-969. doi: 10.1111/cea.13154. Epub 2018 Jun 6.

PMID:
29682796
6.

Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study.

Silkoff PE, Flavin S, Gordon R, Loza MJ, Sterk PJ, Lutter R, Diamant Z, Turner RB, Lipworth BJ, Proud D, Singh D, Eich A, Backer V, Gern JE, Herzmann C, Halperin SA, Mensinga TT, Del Vecchio AM, Branigan P, San Mateo L, Baribaud F, Barnathan ES, Johnston SL.

J Allergy Clin Immunol. 2018 Apr;141(4):1220-1230. doi: 10.1016/j.jaci.2017.06.027. Epub 2017 Jul 20.

7.

Sarcoidosis extent relates to molecular variability.

Monast CS, Li K, Judson MA, Baughman RP, Wadman E, Watt R, Silkoff PE, Barnathan ES, Brodmerkel C.

Clin Exp Immunol. 2017 Jun;188(3):444-454. doi: 10.1111/cei.12942. Epub 2017 Mar 27.

8.

Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients.

Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg CM, Girodet PO, Berger P, Kline JN, Chupp G, Susulic VS, Barnathan ES, Baribaud F, Loza MJ; Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study investigators.

J Allergy Clin Immunol. 2017 Sep;140(3):710-719. doi: 10.1016/j.jaci.2016.11.038. Epub 2017 Jan 13.

PMID:
28089872
9.

Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study.

Loza MJ, Djukanovic R, Chung KF, Horowitz D, Ma K, Branigan P, Barnathan ES, Susulic VS, Silkoff PE, Sterk PJ, Baribaud F; ADEPT (Airways Disease Endotyping for Personalized Therapeutics) and U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome Consortium) investigators.

Respir Res. 2016 Dec 15;17(1):165.

10.

Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study.

Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg C, Girodet PO, Berger P, Kline JN, Khatri S, Chanez P, Susulic VS, Barnathan ES, Baribaud F, Loza MJ; ADEPT Investigators.

Respir Res. 2016 Apr 23;17:43. doi: 10.1186/s12931-016-0360-5.

11.

Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma Studies.

Loza MJ, Adcock I, Auffray C, Chung KF, Djukanovic R, Sterk PJ, Susulic VS, Barnathan ES, Baribaud F, Silkoff PE; ADEPT and U-BIOPRED Investigators.

Ann Am Thorac Soc. 2016 Mar;13 Suppl 1:S102-3. doi: 10.1513/AnnalsATS.201508-519MG.

12.

Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.

Baughman RP, Judson MA, Lower EE, Drent M, Costabel U, Flavin S, Lo KH, Barnathan ES; Sarcoidosis Investigators.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Jan 15;32(4):289-95.

PMID:
26847095
13.

Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.

Silkoff PE, Strambu I, Laviolette M, Singh D, FitzGerald JM, Lam S, Kelsen S, Eich A, Ludwig-Sengpiel A, Hupp GC, Backer V, Porsbjerg C, Girodet PO, Berger P, Leigh R, Kline JN, Dransfield M, Calhoun W, Hussaini A, Khatri S, Chanez P, Susulic VS, Barnathan ES, Curran M, Das AM, Brodmerkel C, Baribaud F, Loza MJ.

Respir Res. 2015 Nov 17;16:142. doi: 10.1186/s12931-015-0299-y.

14.

CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.

Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, Lancaster L, Gibson KF, Haddad T, Agarwal P, Mack M, Dasgupta B, Nnane IP, Flavin SK, Barnathan ES.

Eur Respir J. 2015 Dec;46(6):1740-50. doi: 10.1183/13993003.01558-2014. Epub 2015 Oct 22.

15.

Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure.

Judson MA, Mack M, Beaumont JL, Watt R, Barnathan ES, Victorson DE.

Am J Respir Crit Care Med. 2015 Apr 1;191(7):786-95. doi: 10.1164/rccm.201410-1785OC.

PMID:
25594886
16.

Utility of animal and in vivo experimental infection of humans with rhinoviruses in the development of therapeutic agents for viral exacerbations of asthma and chronic obstructive pulmonary disease.

Del Vecchio AM, Branigan PJ, Barnathan ES, Flavin SK, Silkoff PE, Turner RB.

Pulm Pharmacol Ther. 2015 Feb;30:32-43. doi: 10.1016/j.pupt.2014.10.005. Epub 2014 Nov 13. Review.

PMID:
25445932
17.

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.

Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, Shigemitsu H, Barney JB, Culver DA, Hamzeh NY, Wijsenbeek MS, Albera C, Huizar I, Agarwal P, Brodmerkel C, Watt R, Barnathan ES.

Eur Respir J. 2014 Nov;44(5):1296-307. doi: 10.1183/09031936.00000914. Epub 2014 Jul 17.

18.

Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma.

Barchuk W, Lambert J, Fuhr R, Jiang JZ, Bertelsen K, Fourie A, Liu X, Silkoff PE, Barnathan ES, Thurmond R.

Pulm Pharmacol Ther. 2014 Oct;29(1):15-23. doi: 10.1016/j.pupt.2014.06.003. Epub 2014 Jul 10.

PMID:
25018015
19.

Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma.

Zhu J, Message SD, Qiu Y, Mallia P, Kebadze T, Contoli M, Ward CK, Barnathan ES, Mascelli MA, Kon OM, Papi A, Stanciu LA, Jeffery PK, Johnston SL.

Chest. 2014 Jun;145(6):1219-1229. doi: 10.1378/chest.13-1567.

20.

The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial.

Judson MA, Baughman RP, Costabel U, Mack M, Barnathan ES.

Respir Med. 2014 Jan;108(1):189-94. doi: 10.1016/j.rmed.2013.11.019. Epub 2013 Dec 10.

21.

Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease.

Rennard SI, Flavin SK, Agarwal PK, Lo KH, Barnathan ES.

Respir Med. 2013 Mar;107(3):424-32. doi: 10.1016/j.rmed.2012.11.008. Epub 2012 Dec 14.

22.

Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease.

Loza MJ, Watt R, Baribaud F, Barnathan ES, Rennard SI.

Respir Res. 2012 Feb 2;13:12. doi: 10.1186/1465-9921-13-12.

23.

Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway.

Judson MA, Marchell RM, Mascelli M, Piantone A, Barnathan ES, Petty KJ, Chen D, Fan H, Grund H, Ma K, Baribaud F, Brodmerkel C.

J Am Acad Dermatol. 2012 Jun;66(6):901-10, 910.e1-2. doi: 10.1016/j.jaad.2011.06.017. Epub 2011 Sep 15. Review.

PMID:
21924794
24.

Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis.

Loza MJ, Brodmerkel C, Du Bois RM, Judson MA, Costabel U, Drent M, Kavuru M, Flavin S, Lo KH, Barnathan ES, Baughman RP.

Clin Vaccine Immunol. 2011 Jun;18(6):931-9. doi: 10.1128/CVI.00337-10. Epub 2011 Apr 20.

25.

Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study.

Prati F, Petronio S, Van Boven AJ, Tendera M, De Luca L, de Belder MA, Galassi AR, Imola F, Montalescot G, Peruga JZ, Barnathan ES, Ellis S, Savonitto S; FINESSE-ANGIO substudy investigators.

JACC Cardiovasc Interv. 2010 Dec;3(12):1284-91. doi: 10.1016/j.jcin.2010.08.023.

26.

C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis.

Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R; T48 Investigators.

Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(1):49-56.

PMID:
21086905
27.

Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).

Montalescot G, Ellis SG, de Belder MA, Janssens L, Katz O, Pluta W, Ecollan P, Tendera M, van Boven AJ, Widimsky P, Andersen HR, Betriu A, Armstrong P, Brodie BR, Herrmann HC, Neumann FJ, Effron MB, Lu J, Barnathan ES, Topol EJ; Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events Investigators.

JACC Cardiovasc Interv. 2010 Feb;3(2):203-12. doi: 10.1016/j.jcin.2009.11.012.

28.

Vitronectin concentrations predict risk in patients undergoing coronary stenting.

Derer W, Barnathan ES, Safak E, Agarwal P, Heidecke H, Möckel M, Gross M, Oezcelik C, Dietz R, Dechend R.

Circ Cardiovasc Interv. 2009 Feb;2(1):14-9. doi: 10.1161/CIRCINTERVENTIONS.108.795799. Epub 2008 Dec 15.

PMID:
20031688
29.

Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals.

Herrmann HC, Lu J, Brodie BR, Armstrong PW, Montalescot G, Betriu A, Neuman FJ, Effron MB, Barnathan ES, Topol EJ, Ellis SG; FINESSE Investigators.

JACC Cardiovasc Interv. 2009 Oct;2(10):917-24. doi: 10.1016/j.jcin.2009.06.018.

30.

1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial.

Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Hamankiewicz M, Pluta W, Oldroyd K, Ecollan P, Janssens L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE Investigators.

JACC Cardiovasc Interv. 2009 Oct;2(10):909-16. doi: 10.1016/j.jcin.2009.07.009.

31.

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM; ATLAS ACS-TIMI 46 study group.

Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17.

PMID:
19539361
32.

Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation.

Baughman RP, Shipley R, Desai S, Drent M, Judson MA, Costabel U, du Bois RM, Kavuru M, Schlenker-Herceg R, Flavin S, Lo KH, Barnathan ES; Sarcoidosis Investigators.

Chest. 2009 Aug;136(2):526-535. doi: 10.1378/chest.08-1876. Epub 2009 Apr 24.

PMID:
19395578
33.

A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.

Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P; T03 Asthma Investigators.

Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. doi: 10.1164/rccm.200809-1512OC. Epub 2009 Jan 8.

PMID:
19136369
34.

Facilitated PCI in patients with ST-elevation myocardial infarction.

Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE Investigators.

N Engl J Med. 2008 May 22;358(21):2205-17. doi: 10.1056/NEJMoa0706816.

35.

Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems.

Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, Barnathan ES.

Am J Clin Dermatol. 2008;9(3):155-61.

PMID:
18429644
36.

Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II).

Adams HP Jr, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W; AbESTT-II Investigators.

Stroke. 2008 Jan;39(1):87-99. Epub 2007 Nov 21.

PMID:
18032739
37.

No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial.

Westerhout CM, Gnarpe J, Chang WC, FitzPatrick S, Barnathan ES, Boersma E, Califf RM, Wallentin L, Simoons ML, Armstrong PW; GUSTO IV ACS Investigators.

Am Heart J. 2007 Aug;154(2):306-12. Erratum in: Am Heart J. 2007 Dec;154(6):1242-3.

PMID:
17643581
38.

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.

Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J; COPD Investigators.

Am J Respir Crit Care Med. 2007 May 1;175(9):926-34. Epub 2007 Feb 8.

PMID:
17290043
39.

The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.

Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT.

Am J Respir Crit Care Med. 2006 Oct 1;174(7):753-62. Epub 2006 Jul 13. Retraction in: Am J Respir Crit Care Med. 2011 Feb 1;183(3):418.

PMID:
16840747
40.

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Müller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES; Sarcoidosis Investigators.

Am J Respir Crit Care Med. 2006 Oct 1;174(7):795-802. Epub 2006 Jul 13.

PMID:
16840744
41.

Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis.

Chang WC, Midodzi WK, Westerhout CM, Boersma E, Cooper J, Barnathan ES, Simoons ML, Wallentin L, Ohman EM, Armstrong PW.

J Epidemiol Community Health. 2005 May;59(5):427-33.

42.

Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes.

Mascelli MA, Deliargyris EN, Damaraju LV, Barnathan ES, Califf RM, Simoons ML, Sane DC.

J Thromb Thrombolysis. 2004 Dec;18(3):171-5.

PMID:
15815878
43.

Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS.

Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators.

Eur Heart J. 2004 Sep;25(17):1494-501.

PMID:
15342168
44.

Role of anti-PF4/heparin antibodies in recurrent thrombotic events after acute coronary syndromes.

Mascelli MA, Deliargyris EN, Damaraju LV, Barnathan ES, Sane DC.

Semin Thromb Hemost. 2004 Jun;30(3):347-50.

PMID:
15282657
45.

Final results of the ReoPro readministration registry.

Dery JP, Braden GA, Lincoff AM, Kereiakes DJ, Browne K, Little T, George BS, Sane DC, Cines DB, Effron MB, Mascelli MA, Langrall MA, Damaraju L, Barnathan ES, Tcheng JE; ReoPro Readministration Registry Investigators.

Am J Cardiol. 2004 Apr 15;93(8):979-84.

PMID:
15081439
46.

Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.

Nakada MT, Montgomery MO, Nedelman MA, Guerrero JL, Cohen SA, Barnathan ES, Jordan RE.

J Vasc Interv Radiol. 2004 Feb;15(2 Pt 1):169-76.

PMID:
14963184
47.

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.

James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L.

Circulation. 2003 Jul 22;108(3):275-81. Epub 2003 Jul 7.

PMID:
12847065
48.

Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes.

Williams RT, Damaraju LV, Mascelli MA, Barnathan ES, Califf RM, Simoons ML, Deliargyris EN, Sane DC.

Circulation. 2003 May 13;107(18):2307-12. Epub 2003 Apr 21.

PMID:
12707235
49.

Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.

Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol E, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators.

Circulation. 2003 Jan 28;107(3):437-42.

PMID:
12551868
50.

Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects.

Freedman J, Mascelli MA, Pezzullo JC, Barnathan ES, Frederick B, Jordan RE, Abernethy DR.

Am Heart J. 2002 Jan;143(1):87-94.

PMID:
11773917

Supplemental Content

Loading ...
Support Center